- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC | 3 | Seeking Alpha | ||
| Mo | BeyondSpring berichtet über sicherere Therapieoption für NSCLC | 1 | Investing.com Deutsch | ||
| Mo | BeyondSpring reports safer NSCLC therapy option | 10 | Investing.com | ||
| Mo | BeyondSpring reports promising phase 2 NSCLC study results | 10 | Investing.com | ||
| Mo | BeyondSpring, Inc.: BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 | 51 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer... ► Artikel lesen | |
| Mo | BeyondSpring, Inc.: BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 | 53 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer... ► Artikel lesen | |
| 03.09. | BeyondSpring, Inc.: BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin | 1 | GlobeNewswire (USA) | ||
| 29.08. | BeyondSpring Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.08. | BeyondSpring Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.08. | BeyondSpring, Inc.: SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications | 137 | GlobeNewswire (Europe) | The SEED-Eisai Research Collaboration leverages Eisai's leading expertise in neurodegeneration and cancer. SEED is entitled to receive upfront and milestone payments of up to $1.5 billion plus tiered... ► Artikel lesen | |
| 12.06. | BeyondSpring files to offer up to 10M ordinary shares | 1 | Seeking Alpha | ||
| 12.06. | BeyondSpring Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.05. | BeyondSpring, Inc.: BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics | 1 | GlobeNewswire (USA) | ||
| 03.05. | BeyondSpring, Inc.: BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics | 1 | GlobeNewswire (USA) | ||
| 30.04. | BeyondSpring GAAP EPS of -$1.64, revenue of $1.35M | 1 | Seeking Alpha | ||
| 29.04. | BeyondSpring, Inc.: BeyondSpring Files 2023 Annual Report on Form 20-F | 1 | GlobeNewswire (USA) | ||
| 29.04. | BeyondSpring, Inc.: BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results | 151 | GlobeNewswire (Europe) | - BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination Studies - SITC 2023 Presentation of the Phase 1 Topline Clinical and Mechanism... ► Artikel lesen | |
| 29.04. | BeyondSpring Inc. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 25.03. | BeyondSpring, Inc.: BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer | 68 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 10.01. | BeyondSpring, Inc.: BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K | 78 | GlobeNewswire (Europe) | NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company focused on using a groundbreaking... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,035 | -0,38 % | Biotech Report: Biontech gesucht, Qiagen behauptet | (shareribs.com) Frankfurt / New York 16.09.2024 - Biotech-Aktien zeigten sich zum Wochenauftakt im deutschen Handel uneinheitlich. Für Biotest und Evotec ging es abwärts. Qiagen konnten sich behaupten.... ► Artikel lesen | |
| BIONTECH | 100,50 | -0,20 % | BioNTech Aktie: Dreht der Aktienkurs nach der langen Baisse nun endgültig nach oben? | Interessant geht es aktuell bei der BioNTech Aktie zu: Während der Aktienkurs des Konkurrenten Moderna gestern angesichts schlechter Nachrichten zur Prognose massiv an Wert verlor, ging es für den Aktienkurs... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 29,510 | 0,00 % | Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge | ||
| EVOTEC | 6,345 | -1,78 % | Bayer, Commerzbank, Evotec, Gold, Valneva - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,140 | 0,00 % | ROUNDUP/Aktien New York: Neue Rekorde vor US-Zinsentscheid | NEW YORK (dpa-AFX) - Vor dem Zinsentscheid der US-Notenbank Fed bleiben die Anleger an den New Yorker Börsen optimistisch. Der Leitindex Dow Jones Industrial markierte am Dienstag gleich zu Beginn... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,730 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Set to Join S&P SmallCap 600 Index | RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 45,670 | +2,33 % | Unveiling 7 Analyst Insights On Avidity Biosciences | ||
| DYNE THERAPEUTICS | 36,420 | +6,06 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| TELESIS BIO | 2,930 | 0,00 % | HotStocks USA: Rezolve AI + 207%, Telesis Bio + 167 % | ||
| NUVALENT | 103,21 | 0,00 % | Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates | ||
| ARCELLX | 85,46 | 0,00 % | ACLX, HROW Deliver Triple-Digit Returns - Did You Cash In? | WASHINGTON (dpa-AFX) - Many traders seek instant gratification in the stock market. Some stocks offer quick profits, while others require a patient, long-term approach for significant returns.... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 38,800 | +1,41 % | Structure Therapeutics Inc.: Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer | SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| MODERNA | 61,03 | +0,13 % | Kursverluste für das Wertpapier von Moderna (60,30 €) | Im Minus liegt aktuell die Aktie von Moderna . Die Aktie kostete zuletzt 60,30 Euro. Heute hat sich am US-amerikanischen Aktienmarkt das Wertpapier von Moderna zwischenzeitlich um 4,24 Prozent verbilligt.... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 35,320 | -0,73 % | SpringWorks Therapeutics, Inc.: FDA Grants Priority Review to SpringWorks Therapeutics' New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN | - PDUFA target action date of February 28, 2025 - - EU Marketing Authorization Application also validated by European Medicines Agency - STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,930 | 0,00 % | Angle PLC Announces Agreement with Recursion Pharmaceuticals | New pharma agreement for Parsortix CTC analysisGUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating... ► Artikel lesen |
BEYONDSPRING INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,080 (+3,74 %) liegt der Kurs bei 2,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BEYONDSPRING INC finden Sie auf Wallstreet Online.
